secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001641172-25-001895
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics reports FY2024 revenue up 9% to $15M; operating loss narrows 35%
--------------------------------------------------------------------------------

- Revenue $15.0M (+9% YoY); product revenue increased 26%; gross profit $9.0M at 60% margin.
- Operating loss reduced 35% to $11.2M from $17.3M; operating expenses down 21%.
- Cash $6.3M; raised $17.9M via four equity transactions including $7.5M from New Seneca Partners.
- FDA 510(k) clearance for DNA appliance to treat moderate-to-severe OSA in children ages 6-17.
- New strategic alliance with Rebis Health; expects 4-6x increase in revenue per case under new distribution model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000164117225001895/0001641172-25-001895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000164117225001895/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-001895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer